EMAN RESEARCH PUBLISHING | <p>Tumor angiogenesis and its current treatment: a short review</p>
Inflammation Cancer Angiogenesis Biology and Therapeutics | Impact 0.1 (CiteScore) | Online ISSN  2207-872X
REVIEWS   (Open Access)

Tumor angiogenesis and its current treatment: a short review

Dhamraa Waleed Ahmed

+ Author Affiliations

Journal of Angiotherapy 1(1) 044-047 https://doi.org/10.25163/angiotherapy.11001121108100517

Submitted: 11 September 2016  Revised: 13 February 2017  Published: 10 May 2017 


Angiogenesis is the process of formation new blood vessel. This process involves the migration, differentiation and growth of endothelial cells that line the inside wall of blood vessels (Folkman, 2007). Angiogenesis and inflammation, two host-dependent and interdependent hallmarks of cancer, play a critical role in the growth and spread of cancer. Tumors can stimulate angiogenesis by giving off chemical signals to increase blood flow to the tumor by promoting nearby normal cells to produce angiogenesis signaling molecules (Sturk, 2005). During critical tumor growth, the diffusion of nutrients and oxygen to the center of the tumor can become difficult, which causes a state of cellular hypoxia that marks the onset of tumoral angiogenesis. New blood vessel development during tumor progression favors the transition from hyperplasia to neoplasia or the passage from a state of steady-state cellular division to a state of uncontrolled proliferation, characteristic of tumor cells. This state then influences the dissemination of cancer cells throughout the entire body (metastasis formation). On the other side, there is anti-angiogenesis mechanisms process interfere with blood vessel formation (Eichhorn, 2007).

Keywords: VEGF, vascular endothelial growth factor


Béliveau R, Gingras D. (2004). Green tea: prevention and treatment of cancer by nutraceuticals. Lancet, 364, 1021-2.

Chipault, J.R. (1962). Antioxidants for Use in Foods. In Autoxidation and Antioxidants; Lundberg, W.O.,Ed.; Wiley: New York, NY, USA, 2, 477–542.

Chemoprevention Working Group. (1999). Prevention of cancer in the next millennium: report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Research, 59(19), 4743–4758.

Critchfield K.L. (2012). Tailoring common treatment principles to fit individual personalities. J. Personal. Disord., 26, 108–125.

Curèiæ M.G., Stankoviæ M.S., Mrkaliæ E.M., Matoviæ Z.D., Bankoviæ D.D., Montero A.J., et al. (2012). Phase II study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer. Breast Cancer Res. Treat., 132, 215–223.

Cvetkoviæ D.M., Daèiæ D.S., Markoviæ S.D. (2012). Antiproliferative and proapoptotic activities of methanolic extracts from Ligustrum vulgare L. as an individual treatment and in combination with palladium complex. Int. J. Mol. Sci., 13, 2521–2534.

Domenico Ribatti, Maria Teresa Conconi, And Gastone G. (2007). Nussdorfer: Nonclassic Endogenous Novel Regulators of Angiogenesis. Pharmacol Rev, 59, 185–205.

Du B., Jiang L., Xia Q., Zhong L. (2006). Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy, 52, 23–28.

Eichhorn, M. E., A. Kleespies, et al. (2007). Angiogenesis in cancer: molecular mechanisms, clinical impact." Langenbecks Arch Surg., 392(3), 371-9.

Folkman J. (2007). Angiogenesis: an organizing principle for drug discovery. Nat Rev Drug Discov., 6, 273–286.

Kruger, A. P. H. Duray, D. K. Price, J. M. Pluda, and W. D. Figg. (2001). Approaches to preclinical screening of antiangiogenic agents. Seminars in Oncology, 28(6), 570–576.

Ribatti D, Nico B, Crivellato E, Roccaro AM, and Vacca A. (2007). The history of the angiogenic switch concept. Leukemia, 21, 44-52.

Rose, D.P.; Connolly, J.M. (2000). Regulation of tumor angiogenesis by dietary fatty acids andeicosanoids. Nutr. Cancer, 37, 119–127.

Sturk C, Dumont D. In: Tannock IF, Hill RP, Bristow RG, et al. (2005). eds. Basic Science of Oncology. 4th ed. New York, NY: McGraw-Hill, 231-248.

Schafer, M. and S. Werner. (2008). Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol, 9(8), 628-38.

Schugart RC, Friedman A, Zhao R, Sen CK. (2008). Wound angiogenesis as a function of tissue oxygen tension: a mathematical model. Proc Natl Acad Sci USA, 105, 2628–2633.

Secord A.A., Berchuck A., Higgins R.V., Nycum L.R., Kohler M.F., Puls L.E., Holloway R.W., Lewandowski G.S., Valea F.A., Havrilesky L.J. (2012). A multicenter, randomized, phase II clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Cancer, 118:3283–3293.

Shankel, D.M.; Pillai, S.P.; Telikepalli, H.; Menon, S.R.; Pillai, C.A.; Mitscher, L.A. (2000). Role of antimutagens/anticarcinogens in cancer prevention. Biofactors, 12, 113–121.

Sharma, M. Ghoddoussi, P. Gao, G. J. Kelloff, V. E. Steele, and L. Kopelovich. (2001). A quantitative angiogenesis model for efficacy testing of chemopreventive agents. Anticancer Research, 21(6), 3829–3837.

Sharma G, Tyagi AK, Singh RP, Chan DC, Agarwal R. (2004). Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells. Breast Cancer Res Treat., 85, 1–12.

Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, et al. (2004).  Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res, 10, 8641-7.

Tosetti F,Ferrari N, De Flora S, Albini A. (2002). Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J, 16(1), 2-14.

Tsao, A.S.; Kim, E.S.; Hong, W.K. (2004). Chemoprevention of cancer. CA Cancer J. Clin., (2004), 54,150–180.

Urba S., van Herpen C.M., Sahoo T.P., Shin D.M., Licitra L., Mezei K., Reuter C., Hitt R., Russo F., Chang S.C., et al. (2012). Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: Final results of a randomized, double-blind, placebo-controlled, phase III study. Cancer., 118, 4694–4705.

Vu TH, Werb Z. (2000). Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev., 14, 2123–2133.

Wang J.Y., Swami S., Krishnan A.V., Feldman D. (2012). Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer. Prostate. 72, 1628–1637.

Wattenberg LW. (1996). Chemoprevention of cancer. Prev Med., (1), 44-5.

Committee on Publication Ethics

Full Text
Export Citation

View Dimensions

View Plumx

View Altmetric